Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 19/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | MC4R | P32245 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21675747 | 0.84 | PTGS2 (0.72) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL6672818 | 0.84 | PTGS2 (0.72) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL21675748 | 0.83 | PTGS2 (0.71) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| 5-Hydroxy Rofecoxib SCHEMBL6331980 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL17917317 | 0.81 | PTGS2 (0.67) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL7958864 | 0.80 | PTGS2 (0.70) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL6676482 | 0.78 | PTGS2 (0.63) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL6676479 | 0.77 | PTGS2 (0.62) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL8423806 | 0.75 | PTGS2 (0.69) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL7567581 | 0.75 | PTGS2 (0.59) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | disclosed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| EP-1140179-A2 | USE OF A CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000038786-A2 | USE OF CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |